A Non-randomized, Open, Dose Escalation Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LPM3480226 Tablets in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 15 Apr 2019
Price : $35 *
At a glance
- Drugs LY-01013 (Primary)
- Indications Bladder cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Renal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Luye Pharma Group
- 15 Feb 2019 Status changed from planning to recruiting.
- 06 Mar 2018 New trial record
- 26 Jan 2018 According to a Luye Pharma Group media release, clinical trial application for LY01013 is accepted by the China Food and Drug Administration (CFDA).